Press "Enter" to skip to content

New patent for Novo Nordisk drug LEVEMIR INNOLET


Annual Drug Patent Expirations for LEVEMIR+INNOLET
Annual Drug Patent Expirations for LEVEMIR+INNOLET

Levemir Innolet is a drug marketed by Novo Nordisk Inc
and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug.

This drug has seventy-three patent family members in twenty-eight countries.

The generic ingredient in LEVEMIR INNOLET is insulin detemir recombinant. Three suppliers are listed for this compound. Additional details are available on the insulin detemir recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
or visit

Do NOT follow this link or you will be banned from the site!